BRPI0512298A - compostos orgánicos - Google Patents

compostos orgánicos

Info

Publication number
BRPI0512298A
BRPI0512298A BRPI0512298-8A BRPI0512298A BRPI0512298A BR PI0512298 A BRPI0512298 A BR PI0512298A BR PI0512298 A BRPI0512298 A BR PI0512298A BR PI0512298 A BRPI0512298 A BR PI0512298A
Authority
BR
Brazil
Prior art keywords
quinolin
organic compounds
halo
substituted
chiral agent
Prior art date
Application number
BRPI0512298-8A
Other languages
English (en)
Inventor
Oliver Lohse
Caspar Vogel
Gerhard Penn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32799952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0512298(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0512298A publication Critical patent/BRPI0512298A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/04—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D251/06—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS ORGáNICOS. A presente invenção refere-se a um processo para preparar óxi-5-((R)-2-halo-1-hidróxi-etil)-(1H)-quinolin-2-onas substituídas na posição 8 ou solvatos aceitáveis das mesmas. O processo envolve reagir uma 5-(a-haloacetil)-8-substituída óxi-(1H)-quinolin-2-ona com um agente redutor, na presença de um agente quiral e uma base para formar uma óxi-5-((R)-2-halo-1-hidróxi-etil)-(IH)-quinolin-2-ona substituída na posição 8, dito agente quiral tendo fórmula (I) ou (II), em que M, L, X, R¹, R² e R³ têm os significados indicados no relatório descritivo.
BRPI0512298-8A 2004-06-22 2005-06-21 compostos orgánicos BRPI0512298A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413960.6A GB0413960D0 (en) 2004-06-22 2004-06-22 Organic compounds
PCT/EP2005/006686 WO2005123684A2 (en) 2004-06-22 2005-06-21 Enantioselektive preparation of quinoline derivative

Publications (1)

Publication Number Publication Date
BRPI0512298A true BRPI0512298A (pt) 2008-03-25

Family

ID=32799952

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512298-8A BRPI0512298A (pt) 2004-06-22 2005-06-21 compostos orgánicos

Country Status (32)

Country Link
US (2) US20090054653A1 (pt)
EP (1) EP1791820B1 (pt)
JP (1) JP5064214B2 (pt)
KR (1) KR101179302B1 (pt)
CN (1) CN1968927B (pt)
AR (2) AR049553A1 (pt)
AT (1) ATE450512T1 (pt)
AU (1) AU2005254698B2 (pt)
BR (1) BRPI0512298A (pt)
CA (1) CA2566388C (pt)
CY (1) CY1109884T1 (pt)
DE (1) DE602005018076D1 (pt)
DK (1) DK1791820T3 (pt)
EC (1) ECSP067100A (pt)
ES (1) ES2337273T3 (pt)
GB (1) GB0413960D0 (pt)
HR (1) HRP20100087T1 (pt)
IL (1) IL179600A (pt)
MA (1) MA28687B1 (pt)
MX (1) MXPA06014695A (pt)
MY (1) MY142051A (pt)
NO (1) NO339079B1 (pt)
NZ (1) NZ551276A (pt)
PE (1) PE20060304A1 (pt)
PL (1) PL1791820T3 (pt)
PT (1) PT1791820E (pt)
RU (1) RU2383534C2 (pt)
SI (1) SI1791820T1 (pt)
TN (1) TNSN06408A1 (pt)
TW (1) TWI347317B (pt)
WO (1) WO2005123684A2 (pt)
ZA (1) ZA200609257B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150468A (en) 2006-06-30 2014-01-30 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
EP1914227A1 (en) * 2006-08-31 2008-04-23 Novartis AG Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
US8877930B2 (en) 2009-11-04 2014-11-04 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
US8680303B2 (en) 2010-03-01 2014-03-25 Massachusetts Institute Of Technology Epoxidation catalysts
EP2593452B1 (en) 2010-07-14 2017-01-18 Novartis AG Ip receptor agonist heterocyclic compounds
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9115129B2 (en) 2012-01-13 2015-08-25 Novartis Ag Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
AR089698A1 (es) 2012-01-13 2014-09-10 Novartis Ag Compuestos heterociclicos antagonistas del receptor ip
WO2013105058A1 (en) 2012-01-13 2013-07-18 Novartis Ag 7,8- dihydropyrido [3, 4 - b] pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
ES2561353T3 (es) 2012-01-13 2016-02-25 Novartis Ag Sales de un agonista del receptor IP
EP2802583A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
WO2014008640A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
WO2014044288A1 (en) 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
EP3848354B1 (en) 2012-09-21 2022-07-27 Crystal Pharma, S.A.U. Process for the preparation of indacaterol and intermediates thereof
HK1212348A1 (en) 2012-12-19 2016-06-10 Novartis Ag Autotaxin inhibitors
ES2637719T3 (es) 2013-02-13 2017-10-16 Novartis Ag Compuestos heterocíclicos agonistas del receptor IP
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
KR102074543B1 (ko) 2013-03-14 2020-02-06 노파르티스 아게 분무-블렌딩을 통한 분무-건조 제제의 탈무정형화
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
ES2626829T3 (es) 2013-03-27 2017-07-26 Laboratorios Lesvi, S.L. Procedimiento para la fabricación de (R)-5[2-(5,6-dietil-indan-2-ilamino)-1-hidroxietil]-8-hidroxi-(1H)-quinolin-2-ona
US20160168119A1 (en) 2013-07-18 2016-06-16 Novartis Ag Autotaxin inhibitors
MX368059B (es) 2013-07-18 2019-09-18 Novartis Ag Inhibidores de autotaxina que comprenden un núcleo de anillo heteroaromático de bencil-amida cíclica.
PT3092217T (pt) 2014-01-09 2020-09-04 Ramamohan Rao Davuluri Processo inovador para preparação de indacaterol ou dos seus sais farmaceuticamente aceitáveis
KR20160137543A (ko) 2014-03-27 2016-11-30 노파르티스 아게 활성 약제 성분의 흡입을 위한 분무-건조되는 수-중-유-중-고체 분산액
US20170037030A1 (en) 2014-04-24 2017-02-09 Novartis Ag Autotaxin inhibitors
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
KR101769204B1 (ko) * 2015-08-04 2017-08-17 씨제이헬스케어 주식회사 크로마놀 유도체의 신규한 제조방법
ES2747905T3 (es) 2015-09-29 2020-03-12 Inke Sa Solvato mixto de L-tartrato de (R)-5-[2-(5,6-dietilindan-2-ilamino)-1-hidroxietil]-8-hidroxi-1H-quinolin-2-ona
US10418663B2 (en) 2016-05-17 2019-09-17 Industrial Technology Research Institute Metal-ion battery
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN114591236A (zh) * 2020-12-02 2022-06-07 四川海思科制药有限公司 一种茚达特罗的改进制备方法
CN113731406B (zh) * 2021-10-12 2023-07-28 南京工业大学 一种提高钯碳活性加氢脱除保护基的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
EP0952832B1 (en) * 1996-05-20 2008-08-27 Darwin Discovery Limited Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20050211A1 (es) * 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas

Also Published As

Publication number Publication date
GB0413960D0 (en) 2004-07-28
WO2005123684A3 (en) 2006-06-01
DK1791820T3 (da) 2010-04-06
CY1109884T1 (el) 2014-09-10
WO2005123684A2 (en) 2005-12-29
HRP20100087T1 (hr) 2010-06-30
CN1968927B (zh) 2010-07-21
NO339079B1 (no) 2016-11-07
KR20070029752A (ko) 2007-03-14
EP1791820B1 (en) 2009-12-02
TNSN06408A1 (en) 2008-02-22
PE20060304A1 (es) 2006-05-19
ATE450512T1 (de) 2009-12-15
PL1791820T3 (pl) 2010-05-31
EP1791820A2 (en) 2007-06-06
DE602005018076D1 (de) 2010-01-14
CN1968927A (zh) 2007-05-23
JP5064214B2 (ja) 2012-10-31
JP2008503526A (ja) 2008-02-07
IL179600A (en) 2011-11-30
PT1791820E (pt) 2010-02-23
CA2566388A1 (en) 2005-12-29
AU2005254698A1 (en) 2005-12-29
ECSP067100A (es) 2007-01-26
US20090054653A1 (en) 2009-02-26
TW200615265A (en) 2006-05-16
MXPA06014695A (es) 2007-02-12
AR082981A2 (es) 2013-01-23
MA28687B1 (fr) 2007-06-01
MY142051A (en) 2010-08-30
SI1791820T1 (sl) 2010-04-30
US20120220775A1 (en) 2012-08-30
KR101179302B1 (ko) 2012-09-03
IL179600A0 (en) 2007-05-15
ZA200609257B (en) 2008-07-30
AU2005254698B2 (en) 2008-09-25
CA2566388C (en) 2013-04-16
AR049553A1 (es) 2006-08-16
RU2383534C2 (ru) 2010-03-10
NO20070400L (no) 2007-03-21
ES2337273T3 (es) 2010-04-22
TWI347317B (en) 2011-08-21
NZ551276A (en) 2010-06-25
HK1105121A1 (en) 2008-02-01
RU2007102228A (ru) 2008-07-27

Similar Documents

Publication Publication Date Title
BRPI0512298A (pt) compostos orgánicos
UY26513A1 (es) Nuevas piperidinas sustituidas, medicamentos que contienen estos compuestos y procedimiento para su preparación.
CY1109510T1 (el) Επιλεγμενοι ανταγωνιστες toy cgrp, μεθοδος για την παραγωγη τους και για τη χρηση τους ως φαρμακων
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
CL2003002665A1 (es) COMPUESTOS DERIVADOS DE ACIDOS CARBOXILICOS, SUS SALES; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA, Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES DONDE ES NECESARIO UN INHIBIDORE DEL FACTOR Xa Y /O UN INHIBIDOR DE SERINA PROTEASA.
BRPI0413934A (pt) compostos orgánicos
UY28848A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos
ECSP088824A (es) Prolinamidas sustituidas, su preparación y su uso como medicamentos
UY28773A1 (es) Nuevas amidas de ácidos carboxílicos, su preparación y su uso como medicamentos.
TNSN08414A1 (en) Terphenyl derivatives for treatment of alzheimer's disease
BRPI0712889A8 (pt) composto, processo para a preparação de um composto, composto intermediário, e, composição farmacêutica.
BR0208992A (pt) Processo para a preparação de indenos 1,3-substituìdos e compostos azapolicìclicos fundidos com arila
BRPI0418047A (pt) processo para a preparação de derivados de piridina
BRPI0409471B8 (pt) processo para preparação de 2-cianopirrolidinas n-substituídas
BRPI0409154A (pt) processo para a preparação de 5-(haloacetil)-8-(óxi substituìdo)-(1h)-quinolin-2-onas
EA200970497A1 (ru) Производные пиррола, их получение и их применение в терапии
BR0308018A (pt) Composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo, pró-droga, método para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hirolisável in vivo, composição farmacêutica, e, processo para a preparação de um composto ou um seu sal farmaceuticamente aceitável ou um seu éster hidrolisável in vivo
EA200800439A1 (ru) Выбранные cgrp-антагонисты, способ их получения, а также их применение в качестве лекарственных средств
BRPI0416678A (pt) pirazolpirimidinas
AU2001235668A1 (en) Xanthine derivatives, intermediates and use for treating osteoporosis
DE60218525D1 (de) A2a adenosinrezeptorantagonisten
BR0214529A (pt) compostos terapêuticos
BR0009195A (pt) Processo para a preparação de carbamatosheterocìclicos a partir de aza-heterociclos edióxido de carbono
BRPI0413741A (pt) métodos para preparar thip e para preparar um composto, e, composto
DE602005010369D1 (de) 2-thiaquinolizidines als Glycosidase- und Glycosyltransferase-Inhibitoren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]